Nearly half of all SCTs hematopoietic progenitor cell (HPC) contain some degree of ABO blood group incompatibility. ABO blood group is an important consideration in HPC because donor Abs incompatible with the recipient major RBC Ags (A and B) may result in acute hemolysis in the peri-transplant period, whereas recipient Abs to incompatible donor major RBC Ags may cause hemolysis and/or delayed RBC engraftment and prolonged RBC transfusion dependence. Non-ABO blood group Abs, also called minor blood group Abs, can cause similar complications. 1 As a result, even in the setting of an autologous HPC, all previously identified minor RBC Abs must be accounted for in the selection of RBC units for transfusion. Although [2] [3] [4] [5] The incidence of minor RBC Abs complicating HPC is low, with reports ranging from 1 to 8.6%. [2] [3] [4] [5] Once such an Ab has been identified, transfusion with Ag-negative units (or, in severe cases, RBC exchange) is required to prevent hemolysis. 2 Depending on the number of Abs and the degree of ABO incompatibility during the transplant, identifying Ag negative, crossmatch-compatible units may require an extensive search.
The etiology of Abs to minor blood group Ags can be difficult to determine in patients undergoing HPC. In some cases, the Abs are believed to be due to passenger lymphocytes adoptively transferred during the stem cell infusion. 2 In other cases, it is believed that the Abs are produced by recipient B-cells that persist after myeloablation. A third possibility is a primary immune response to minor Ag-mismatched RBCs that were transfused in the posttransplant period.
3 Other than careful monitoring for hemolysis, there are very few measures that could be taken to avoid hemolysis arising from passenger lymphocytes or myeloablation-resistent B-cells. However, adopting a transfusion policy limiting minor Ag mismatches between RBC donors and HPC recipients could prevent post-transplant sensitization to minor RBC Ags.
Opponents to the concept of minor Ag matching between RBC transfusions and HPC recipients would be correct to point out that HPC transplant recipients are profoundly immunosuppressed, and therefore have an impaired capacity to mount an immune response to minor RBC Ags. Although alloimmunization rates to the highly immunogenic D Ag are reported to be greater than 80% among healthy people, 6 the rate of alloimmunization to the D Ag is estimated to be only B20% among general hospital patients 7 and is exceedingly low among immunosuppressed patients undergoing liver transplantation (see Table 1 ). Patients undergoing HPC would be expected to be comparatively more immunosuppressed than patients undergoing liver transplantation, but D Ag alloimmunization in HPC patients may still occur, particularly in Rh-negative recipients with pre-transplant history of D Ag alloimmunization receiving Rh-positive grafts. 8 These factors, in combination with the substantial transfusion needs of the HPC population, may make minor Ag matching seem like an ineffective use of scarce resources.
However, there are convincing arguments in favor of minor RBC Ag matching between RBC transfusions and HPC recipients. First, Frohn et al.
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Casaneuva et al. 16 Ramsey et al. McLeod et al. 21 Atoyebi et al. 22 Cid et al. Abou-Elella et al. 4 Zupań ska et al. www.nature.com/bmt although minor RBC Ag sensitization and Ab formation may be rare among immunosuppressed HPC recipients, the reported cases indicate that it is very difficult to predict which patients will alloimmunize. Second, although alloimmunization events are rare, the implications can be serious and the patient group is highly vulnerable. Third, there would be no conceivable harm to patients by at least attempting to find minor RBC Ag-matched units for transfusion. If Ag-matched units could not be identified, the provision of minor Ag-mismatched blood would be no worse for the patient than the current practice. Fourth, all of the information needed to provide Ag-matched units is theoretically obtainable. Most blood collection centers maintain historical phenotypes on their donors, and HPC donors and HPC recipients would only need to have their minor RBC Ags phenotyped once before transplant. Phenotyping could be accomplished using the same tube of blood sent for blood type and Ab screen testing. Finally, phenotyping the minor blood group Ags of the donor apheresis product could also be used to prevent inadvertent infusion of a mislabeled HPC product. 9 Depending on the clinical scenario, alloimmunization may make it difficult to find compatible blood products for patients during a critical phase of their treatment. Recent data suggest that, like the chronically transfused sickle cell disease population, certain hematologic malignancies have a moderate rate of alloimmunization, despite profound immunosuppression and dysregulation. 10 In addition, the low reported incidence of alloimmunization events does not diminish the need for vigilance. As a comparison, costly gamma irradiators are maintained for the sole purpose of irradiating blood products for the prevention of transfusion-associated graft versus host disease (TA-GVHD), which is rare. Finally, except for the D Ag, there is no post-exposure prophylaxis available to prevent alloimmunization to minor blood group Abs after exposure. Therefore, the only way to prevent alloimmunization is to eliminate alloantigen exposure. Because some centers already provide RhD/CE and K1 Ag-matched RBCs to patients requiring chronic transfusion, such as those with sickle cell anemia or transfusion-dependent thalassemias, it does not seem unreasonable to prevent potentially serious adverse events in the HPC population by providing minor RBC Ag-matched RBCs. On the basis of the recent finding that most Abs formed by chronically transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia are to Rh and Kell Ags, we contend that Rh (D, C, c and E) and Kell matching would eliminate most cases of alloimmunization in the HPC population. 10, 11 In conclusion, it is already accepted that careful Ab screening among HPC patients is needed in order to identify critical minor RBC incompatibilities between donors and recipients before transplant. Despite systemic immunosuppression, a small number of HPC transplants are complicated by clinically significant Abs to minor RBC Ags that seem to be formed after exposure to RBCs via transfusion in the post-transplant period. Although the mechanism underlying alloimmunization to RBC Ags is not well understood, it seems reasonable to consider the provision of Rh (D, C, c and E)-matched RBCs for transfusion to HPC patients in the post-transplant period in order to prevent the Ag exposure required for alloimmunization.
